You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 29, 2024

PROVIGIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Provigil patents expire, and what generic alternatives are available?

Provigil is a drug marketed by Cephalon and is included in one NDA. There is one patent protecting this drug.

This drug has sixty-two patent family members in twenty-eight countries.

The generic ingredient in PROVIGIL is modafinil. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the modafinil profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Provigil

A generic version of PROVIGIL was approved as modafinil by ORBION PHARMS on September 26th, 2012.

  Sign Up

Drug patent expirations by year for PROVIGIL
Drug Prices for PROVIGIL

See drug prices for PROVIGIL

Drug Sales Revenue Trends for PROVIGIL

See drug sales revenues for PROVIGIL

Recent Clinical Trials for PROVIGIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kuwait UniversityEarly Phase 1
The Ottawa HospitalPhase 3
Bruyere Research InstitutePhase 3

See all PROVIGIL clinical trials

Pharmacology for PROVIGIL

US Patents and Regulatory Information for PROVIGIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PROVIGIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 ⤷  Sign Up ⤷  Sign Up
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 ⤷  Sign Up ⤷  Sign Up
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 ⤷  Sign Up ⤷  Sign Up
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 ⤷  Sign Up ⤷  Sign Up
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 ⤷  Sign Up ⤷  Sign Up
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PROVIGIL

See the table below for patents covering PROVIGIL around the world.

Country Patent Number Title Estimated Expiration
Norway 20035211 ⤷  Sign Up
Japan S629103 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 02096401 ⤷  Sign Up
Argentina 033910 NUEVAS FORMULACIONES FARMACEUTICAS DE MODA-FINIL ⤷  Sign Up
Denmark 152207 ⤷  Sign Up
South Korea 101125361 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.